Angiex’s AGX101 Phase I Clinical Trial Supported by Abzena’s Manufacturing Expertise
Angiex continues to make strides in cancer therapy development with its Phase I clinical trial for AGX101, a TM4SF1-targeted antibody-drug conjugate (ADC). This novel therapy aims to disrupt the blood vessels in tumors, addressing aggressive forms of cancer. The collaboration with Abzena, a leading contract development and manufacturing organization (CDMO), has been pivotal in providing the critical manufacturing capabilities needed to move this therapy into early clinical stages.
Manufacturing Chemist reported on this significant collaboration, recognizing Abzena’s role in advancing Angiex’s promising cancer therapy. As a specialized publication covering the latest in pharmaceutical manufacturing and development, Manufacturing Chemist is a key outlet for industry professionals. Their coverage underscores the importance of CDMOs in accelerating the production of innovative therapies like AGX101, contributing to the future of cancer treatment.